Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00206635 · ClinicalTrials.gov registry record
Betaseron 16-Year Long-Term Follow-Up (LTF) in Patients With Relapsing-Remitting Multiple Sclerosis
A clinical trial, sponsored by Bayer.
- Completed
- Registry status
- 432
- Enrollment target
NCT00206635 is a clinical trial that has completed, run by Bayer. The registered enrollment target is 432 participants.
The verdict
NCT00206635 has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- 432 participants
- Enrollment target
Study Summary
The purpose of this follow-up study is to look carefully at the long-term course of multiple sclerosis (MS) and possibly the long-term effects of Betaseron in the patients who were previously enrolled in the original North American study that led to the marketing approval of Betaseron.
Interventions
- DRUG Interferon beta-1b (Betaseron, BAY86-5046)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 432 participants |
| Start Date | 2005-01 |
| Est. Completion | 2005-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00206635
The ClinicalTrials.gov registry entry for NCT00206635 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 432 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Interferon beta-1b (Betaseron, BAY86-5046) is the first listed.
NCT00206635 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00206635 about?
NCT00206635 is a clinical study titled "Betaseron 16-Year Long-Term Follow-Up (LTF) in Patients With Relapsing-Remitting Multiple Sclerosis". The purpose of this follow-up study is to look carefully at the long-term course of multiple sclerosis (MS) and possibly the long-term effects of Betaseron in the patients who were previously enrolled in the original North American study that led to the marketing approval of Betaseron.
What is the current status of trial NCT00206635?
This trial is currently completed. The enrollment target is 432 participants. The study started on 2005-01. Estimated completion is 2005-12.
What interventions are being tested in trial NCT00206635?
The interventions under investigation include: Interferon beta-1b (Betaseron, BAY86-5046) (DRUG).
Who is sponsoring clinical trial NCT00206635?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.